Lazard Asset Management
UTHR icon

Lazard Asset Management’s United Therapeutics UTHR Stock Holding History

Lazard Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Sell
553
-9,679
-95% -$5.45M ﹤0.01% 1566
2026
Q1 		$6.07M Sell
10,232
-7,374
-42% -$3.67M 0.01% 513
2025
Q4 		$8.58M Sell
17,606
-12,123
-41% -$5.65M 0.01% 436
2025
Q3 		$12.5M Sell
29,729
-157
-0.5% -$52.8K 0.02% 385
2025
Q2 		$8.59M Buy
29,886
+447
+2% +$134K 0.01% 581
2025
Q1 		$9.07M Buy
29,439
+3,962
+16% +$1.36M 0.01% 509
2024
Q4 		$8.99M Sell
25,477
-4,795
-16% -$1.76M 0.01% 490
2024
Q3 		$10.8M Sell
30,272
-75,422
-71% -$25.5M 0.01% 451
2024
Q2 		$33.7M Sell
105,694
-9,557
-8% -$2.53M 0.04% 281
2024
Q1 		$26.5M Sell
115,251
-81,822
-42% -$18.5M 0.03% 329
2023
Q4 		$43.3M Buy
197,073
+41,445
+27% +$9.55M 0.05% 235
2023
Q3 		$35.2M Sell
155,628
-9,441
-6% -$2.17M 0.05% 262
2023
Q2 		$36.4M Buy
165,069
+27,192
+20% +$6.02M 0.04% 267
2023
Q1 		$30.9M Buy
137,877
+22,398
+19% +$5.52M 0.04% 312
2022
Q4 		$32.1M Sell
115,479
-49,058
-30% -$12.4M 0.04% 297
2022
Q3 		$34.5M Sell
164,537
-25,677
-13% -$5.74M 0.05% 285
2022
Q2 		$44.8M Sell
190,214
-41,813
-18% -$8.5M 0.06% 254
2022
Q1 		$41.6M Sell
232,027
-71,272
-23% -$13.6M 0.05% 304
2021
Q4 		$65.5M Sell
303,299
-14,218
-4% -$2.79M 0.07% 242
2021
Q3 		$58.6M Sell
317,517
-36,419
-10% -$7.17M 0.07% 252
2021
Q2 		$63.5M Buy
353,936
+49,613
+16% +$9.45M 0.07% 231
2021
Q1 		$50.9M Buy
304,323
+58,532
+24% +$9.76M 0.06% 247
2020
Q4 		$37.3M Buy
245,791
+30,955
+14% +$4.06M 0.05% 317
2020
Q3 		$21.7M Buy
214,836
+3,342
+2% +$367K 0.03% 375
2020
Q2 		$25.6M Buy
+211,494
New +$23.8M 0.04% 330
2019
Q2 		– Sell
-9,879
Closed -$1.16M – 1252
2019
Q1 		$1.16M Sell
9,879
-316
-3% -$36.8K ﹤0.01% 826
2018
Q4 		$1.11M Hold
10,195
– – ﹤0.01% 709
2018
Q3 		$1.3M Buy
+10,195
New +$1.26M ﹤0.01% 707
2018
Q1 		– Sell
-17
Closed -$2K – 1126
2017
Q4 		$2K Hold
17
– – ﹤0.01% 1048
2017
Q3 		$1K Sell
17
-1
-6% -$128 ﹤0.01% 976
2017
Q2 		$2K Sell
18
-37,443
-100% -$4.67M ﹤0.01% 990
2017
Q1 		$5.07M Sell
37,461
-56,018
-60% -$8.49M 0.01% 553
2016
Q4 		$13.4M Buy
93,479
+6,298
+7% +$804K 0.03% 364
2016
Q3 		$10.3M Buy
87,181
+3,700
+4% +$445K 0.02% 411
2016
Q2 		$8.84M Sell
83,481
-159,607
-66% -$17.8M 0.02% 420
2016
Q1 		$27.1M Buy
243,088
+48,537
+25% +$6.14M 0.06% 200
2015
Q4 		$30.5M Buy
194,551
+49,334
+34% +$7.18M 0.07% 193
2015
Q3 		$19.1M Sell
145,217
-124,977
-46% -$20M 0.05% 234
2015
Q2 		$47M Buy
270,194
+24,835
+10% +$4.47M 0.1% 169
2015
Q1 		$42.3M Buy
245,359
+133,988
+120% +$20.4M 0.09% 175
2014
Q4 		$14.4M Buy
111,371
+48,259
+76% +$6.22M 0.03% 322
2014
Q3 		$8.12M Buy
63,112
+39,330
+165% +$4.05M 0.02% 427
2014
Q2 		$2.1M Sell
23,782
-32,549
-58% -$3.13M ﹤0.01% 643
2014
Q1 		$5.3M Hold
56,331
– – 0.01% 477
2013
Q4 		$6.37M Hold
56,331
– – 0.01% 460
2013
Q3 		$4.44M Hold
56,331
– – 0.01% 516
2013
Q2 		$3.71M Buy
+56,331
New +$3.63M 0.01% 548

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lazard Asset Management's UTHR Position: Q2 2026 in Review

Lazard Asset Management reduced its United Therapeutics (UTHR) stake by 95% in Q2 2026, selling an estimated $5.45M and leaving 553 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

Lazard Asset Management first reported a position in UTHR in Q2 2013 and has held it in 47 quarters since. The position peaked at $65.5M in Q4 2021. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Lazard Asset Management held 553 shares of United Therapeutics worth $300K as of Q2 2026.
  • Lazard Asset Management sold 9,679 United Therapeutics shares in Q2 2026, an estimated $5.45M.
  • United Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1566 holding.
  • Lazard Asset Management first reported a position in United Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • Lazard Asset Management's United Therapeutics position peaked at $65.5M in Q4 2021.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.